Both groups showed no statistically significant differences in age at primary diagnosis, WHO-grading, histopathology, MGMT methylation status, IDH mutation frequency, pre-operative contrast-enhancing tumor volume (CE volume), or residual contrast-enhancing tumor volume (CE residual) (Table 1). The gene discussed is MGMT; the disease is neoplasm.